Author information:
(1)From the Department of Investigational Cancer Therapeutics, Phase I Clinical 
Trials Program, University of Texas M.D. Anderson Cancer Center, Houston 
(D.S.H., F.M.-B.); the Department of Medical Oncology and Experimental 
Therapeutics, City of Hope Comprehensive Cancer Center, Duarte (M.G.F.), the 
University of California, San Francisco, San Francisco (P.N.M.), and Amgen, 
Thousand Oaks (H.H., J.N., G.N., J.K., B.E.H., J.C., J.R.L., G.F.) - all in 
California; Duke University Medical Center, Durham, NC (J.H.S.); Royal Melbourne 
Hospital/Peter MacCallum Cancer Centre, Melbourne, VIC (J.D.), Queen Elizabeth 
Hospital and University of Adelaide, Woodville South, SA (T.J.P.), and Scientia 
Clinical Research, Randwick, NSW (J.C. Kuo) - all in Australia; the Department 
of Medicine, Division of Hematology/Oncology, Indiana University School of 
Medicine, Indianapolis (G.A.D.); Dana-Farber Cancer Institute, Harvard Medical 
School, Boston (G.I.S.); the Sarah Cannon Research Institute at HealthONE, 
Denver (G.S.F.); Princess Margaret Cancer Centre, University Health Network, 
Toronto (A.S.); Fox Chase Cancer Center, Philadelphia (C.S.D.); the University 
of Pittsburgh Medical Center Hillman Cancer Center, University of Pittsburgh, 
Pittsburgh (T.F.B.); Seoul National University College of Medicine (Y.-J.B.), 
Samsung Medical Center, Sungkyunkwan University School of Medicine (K.P.), and 
the Department of Oncology, Asan Medical Center, University of Ulsan College of 
Medicine (T.W.K.) - all in Seoul, South Korea; Roswell Park Cancer Institute, 
Buffalo (G.K.D.), and Memorial Sloan Kettering Cancer Center and Weill Cornell 
Medicine, New York (P.L., B.T.L.) - all in New York; the University of Michigan, 
Ann Arbor (J.C. Krauss); the Department of Experimental Therapeutics, National 
Cancer Center Hospital East, Kashiwa, Japan (Y.K.); the Department of Medicine, 
Division of Oncology, University of Washington, Seattle (A.L.C.); Aix Marseille 
University, Centre National de la Recherche Scientifique, INSERM, Centre de 
Recherche en Cancérologie de Marseille, Assistance Publique-Hôpitaux de 
Marseille, Marseille, France (F.B.); Winship Cancer Institute of Emory 
University, Atlanta (S.S.R.); and the Alvin J. Siteman Cancer Center at 
Washington University School of Medicine, St. Louis (R.G.).